Syneos on Inflammatory diseases: " Our broad r
Post# of 155579
(Total Views: 651)
Posted On: 08/23/2024 7:03:59 PM
Syneos on Inflammatory diseases:
" Our broad range of global and local knowledge in autoimmune and inflammatory disease research is second to none. "
" Our therapeutic experts have participated in the writing or review of a wide variety of study protocols in immunology and inflammation. With their extensive experience, they play a crucial role in identifying criticalities in your protocols and suggesting adaptations that can facilitate recruitment and prevent the need for amendments in the course of the study."
I read that as ---- having positive Safety Board reviews, if you do Interim Readouts.
: )
https://www.syneoshealth.com/therapeutic-dept...flammation
___________
2018 webinar.
Haven't looked back further.
I think given Syneos stature, 6 yrs is good.
https://www.syneoshealth.com/insights-hub/cli...n-targeted
____________
Our chronic inflammation protocol is of cours, going to be a stunner of design.
Speaks to the power of LL, & obviously today solidified that Dr. J is not seeing FDA roadblocks.
Pr a week ago --- We remain on-track to begin trials.
Yes sir.
Yes sir.
What a dawn of a new day, 2024 is turning into.
So much more to come.
" Our broad range of global and local knowledge in autoimmune and inflammatory disease research is second to none. "
" Our therapeutic experts have participated in the writing or review of a wide variety of study protocols in immunology and inflammation. With their extensive experience, they play a crucial role in identifying criticalities in your protocols and suggesting adaptations that can facilitate recruitment and prevent the need for amendments in the course of the study."
I read that as ---- having positive Safety Board reviews, if you do Interim Readouts.
: )
https://www.syneoshealth.com/therapeutic-dept...flammation
___________
2018 webinar.
Haven't looked back further.
I think given Syneos stature, 6 yrs is good.
https://www.syneoshealth.com/insights-hub/cli...n-targeted
____________
Our chronic inflammation protocol is of cours, going to be a stunner of design.
Speaks to the power of LL, & obviously today solidified that Dr. J is not seeing FDA roadblocks.
Pr a week ago --- We remain on-track to begin trials.
Yes sir.
Yes sir.
What a dawn of a new day, 2024 is turning into.
So much more to come.
(10)
(0)